Blepharitis (Adult)

1. Clinical Overview

Summary

Blepharitis is a chronic inflammatory condition affecting the eyelid margins, representing one of the most common causes of ocular surface disease encountered in clinical practice. [1] The condition is characterised by inflammation of the anterior (lash-bearing) or posterior (meibomian gland-bearing) lid margin, or more commonly a combination of both. The TFOS International Workshop on Meibomian Gland Dysfunction established the modern classification framework, distinguishing anterior blepharitis (staphylococcal and seborrhoeic subtypes) from posterior blepharitis (meibomian gland dysfunction, MGD). [2]

Meibomian gland dysfunction has emerged as the leading cause of evaporative dry eye disease worldwide, affecting up to 70% of Asian and 20% of Caucasian populations in epidemiological studies. [3] The pathophysiology involves terminal duct obstruction with qualitative and quantitative changes in meibomian gland secretion, leading to tear film instability and ocular surface inflammation. The condition follows a chronic, relapsing course requiring long-term management rather than definitive cure.

Demodex infestation represents an increasingly recognised contributor to blepharitis, with Demodex folliculorum inhabiting lash follicles and Demodex brevis colonising meibomian glands. [4] Prevalence increases with age, affecting over 80% of individuals older than 60 years. Associated dermatological conditions, particularly rosacea, demonstrate strong bidirectional relationships with posterior blepharitis, necessitating multidisciplinary management approaches.

Key Clinical Facts

Clinical Pearls for Practice

"Anterior = Lashes, Posterior = Glands": Anterior blepharitis manifests with collarettes (dandruff-like scales) around lash bases with lid margin hyperaemia. Posterior blepharitis (MGD) presents with capped, inspissated meibomian gland orifices and altered meibum quality. Most patients have mixed disease.

Screen for Rosacea: The TFOS DEWS II Report emphasises that 50-65% of rosacea patients have concurrent MGD. [7] Enquire about facial flushing, telangiectasia, papulopustular lesions, and rhinophyma. Consider dermatology co-management.

Unilateral Blepharitis = Red Flag: Blepharitis is characteristically bilateral and symmetric. Unilateral disease, particularly with madarosis (lash loss), treatment resistance, or recurrent chalazion in the same location, mandates biopsy to exclude sebaceous gland carcinoma—a deadly masquerader. [8]

Cylindrical Dandruff = Demodex: The pathognomonic finding of cylindrical collarettes clasping lash bases (versus the flat scales of staphylococcal blepharitis) is highly suggestive of Demodex infestation. [4] Treat with tea tree oil-based lid hygiene products.

Sustained Warmth Matters: The meibomian gland lipid melting point is approximately 32-35°C. Effective warm compress therapy requires sustained temperature of ≥40°C for 10 minutes to liquefy inspissated meibum. [6,9] Reheatable eye masks outperform warm flannels for temperature maintenance.

Why This Matters

Blepharitis accounts for a substantial proportion of ophthalmic consultations and primary care eye complaints. While rarely sight-threatening, the chronic, relapsing nature causes significant patient morbidity and healthcare resource utilisation. Understanding the pathophysiological distinction between anterior and posterior subtypes, recognition of associated systemic conditions, and implementation of evidence-based lid hygiene protocols enables effective long-term symptom control. The critical red flag of unilateral, treatment-resistant disease must prompt consideration of masquerading malignancy.

---

2. Epidemiology

Prevalence and Incidence

The epidemiology of blepharitis reveals a highly prevalent condition with significant global variation related to ethnic and environmental factors. [1,3]

Incidence data are limited due to the chronic, insidious onset, but UK primary care data suggest 5-10 new presentations per 1,000 patient-years.

Demographics and Risk Factors

Age-Related Meibomian Gland Changes

The progressive decline in meibomian gland function with age represents a key epidemiological and pathophysiological feature. [10]

Anatomical Changes:

• Gland Atrophy: Meibography demonstrates progressive gland dropout with age, visible as loss of gland tissue and shortening
• Acinar Atrophy: Histologically, acinar cells undergo atrophy and keratinisation
• Duct Changes: Terminal duct obstruction from hyperkeratinisation

Functional Changes:

• Meibum Quality: Lipid composition alters with increased saturation and higher melting point
• Meibum Quantity: Reduced expressible meibum volume
• Tear Film Stability: Tear break-up time (TBUT) decreases with age

Hormonal Influences:

• Androgens (testosterone, DHEA) are primary regulators of meibomian gland function
• Post-menopausal oestrogen/androgen imbalance adversely affects glands
• Androgen receptor expression decreases with age

Environmental and Lifestyle Factors

---

3. Pathophysiology

Classification System

The TFOS International Workshop on MGD (2011) established the definitive classification framework. [2]

Meibomian Gland Dysfunction: Detailed Pathophysiology

Normal Meibomian Gland Function:

The meibomian glands are modified sebaceous glands (approximately 25-30 in upper lid, 20-25 in lower lid) that secrete meibum, a complex lipid mixture. [2] Meibum forms the outermost tear film lipid layer (TFLL), which:

• Prevents aqueous tear evaporation
• Provides a smooth optical surface
• Reduces surface tension at the air-tear interface
• Has antimicrobial properties

Pathophysiological Cascade in MGD:

1. Hyperkeratinisation of Terminal Ducts

   • Epithelial cell turnover abnormality at duct orifices
   • Keratinised debris accumulates within ducts
   • Triggered by inflammation, hormonal changes, or environmental factors

2. Meibum Stasis and Inspissation

   • Blocked ducts prevent normal meibum expression with blinking
   • Retained meibum undergoes compositional changes
   • Lipid saturation increases; melting point rises
   • Creates a vicious cycle of worsening obstruction

3. Glandular Damage and Atrophy

   • Back-pressure causes acinar dilatation initially
   • Prolonged obstruction leads to acinar atrophy
   • Progressive, irreversible gland dropout (visible on meibography)
   • Once glands are lost, they cannot regenerate

4. Tear Film Instability

   • Deficient lipid layer fails to retard evaporation
   • Tear break-up time decreases
   • Hyperosmolarity develops in the tear film
   • Evaporative dry eye disease ensues

5. Ocular Surface Inflammation

   • Hyperosmolar stress triggers inflammatory cascades
   • Increased IL-1, IL-6, TNF-α, MMP-9 levels
   • Epithelial cell damage and apoptosis
   • Inflammatory mediators further worsen MGD (positive feedback loop)

Staphylococcal Blepharitis Pathophysiology

Staphylococcus aureus and S. epidermidis colonise the lid margin in anterior blepharitis. [1]

Mechanisms of Disease:

• Direct bacterial infection: Chronic low-grade infection at lash follicles
• Exotoxin production: Bacterial toxins cause direct tissue damage
• Immune-mediated damage: Type III and IV hypersensitivity reactions to bacterial antigens
• Superantigen effect: Can trigger widespread immune activation
• Biofilm formation: Creates treatment-resistant bacterial communities

Associated Findings:

• Marginal keratitis: Corneal infiltrates at limbus due to immune response to bacterial antigens
• Phlyctenular keratoconjunctivitis: Delayed hypersensitivity reaction
• Inferior corneal pannus: In chronic cases

Demodex Blepharitis

Demodex mites are obligate human ectoparasites that increase in prevalence with age. [4,13]

Pathogenic Mechanisms:

1. Mechanical damage: Physical blocking of follicles and glands
2. Waste product irritation: Mite faeces and decomposition products cause inflammation
3. Vector for bacteria: Bacillus oleronius (found within mites) may contribute to inflammation [14]
4. Immune response: Delayed-type hypersensitivity to mite antigens

Diagnosis:

• Cylindrical dandruff (collarettes) clasping lash base is pathognomonic
• Epilation and microscopy shows mites (gold standard)
• Prevalence: 1-2 mites/4 lashes = normal; > 4 mites/4 lashes = infestation [4]

Rosacea-Associated MGD

The association between ocular rosacea and MGD is well-established. [7,15]

Shared Pathophysiology:

• Vascular dysregulation and telangiectasia
• Increased matrix metalloproteinase (MMP) activity
• Cathelicidin (LL-37) dysregulation
• Similar inflammatory cytokine profiles
• Demodex mite association with both conditions

Clinical Features of Ocular Rosacea:

• Posterior blepharitis/MGD (most common)
• Chronic conjunctival injection
• Corneal neovascularisation
• Marginal/central corneal infiltrates
• Recurrent chalazia

---

4. Clinical Presentation

Symptoms

Patients with blepharitis present with a characteristic constellation of symptoms, though severity varies considerably. [1,2]

Symptom Patterns:

• Diurnal Variation: Staphylococcal blepharitis often worse in morning (crusting overnight); MGD/evaporative symptoms often worse in evening
• Environmental Exacerbation: Air conditioning, screen use, wind, low humidity worsen symptoms
• Chronic, Fluctuating Course: Periods of exacerbation and relative remission are typical

Clinical Signs

Anterior Blepharitis Signs

Posterior Blepharitis (MGD) Signs

Demodex-Specific Signs

Corneal and Conjunctival Signs

Severity Grading

The TFOS MGD Workshop proposed a severity grading system. [2]

---

5. Clinical Examination

Systematic Examination Approach

A structured slit lamp examination is essential for accurate diagnosis and classification. [1,2]

Pre-Examination Assessment:

• Note patient's blinking pattern (incomplete blink common in MGD)
• Observe facial features (rosacea, seborrhoeic dermatitis)
• Check for glasses, contact lens wear

Step 1: External Inspection (Before Slit Lamp)

• Facial skin: rosacea features (telangiectasia, erythema, rhinophyma)
• Periorbital skin: seborrhoeic dermatitis, eczema
• Lid position and symmetry

Step 2: Slit Lamp Examination - Low Magnification

• Overall lid margin appearance
• Lash distribution and direction
• Tear film quality (debris, foam, mucous strands)

Step 3: Slit Lamp Examination - High Magnification

Lid Margin Assessment:

Meibomian Gland Expression (Diagnostic Meibum Expression - DME):

• Apply gentle digital pressure to lower lid over tarsal plate
• Observe meibum quality from orifices
• Grade: Clear (0) → Cloudy (1) → Granular (2) → Inspissated/None (3)

Step 4: Tear Film Assessment

Step 5: Corneal Examination

• Fluorescein staining: SPK pattern and distribution
• Rose Bengal/Lissamine green: Devitalised epithelium
• Check for marginal keratitis (infiltrates with clear zone from limbus)
• Corneal vascularisation (pannus)

Step 6: Conjunctival Examination

• Injection pattern (limbal vs. diffuse)
• Papillary or follicular response
• Lid-parallel conjunctival folds (LIPCOFs)

Meibography

Meibography provides objective imaging of meibomian gland morphology. [2,16]

Technique:

• Infrared imaging of everted upper and lower lids
• Non-invasive; part of comprehensive MGD assessment
• Available on many modern slit lamp imaging systems

Grading (Meiboscore):

Clinical Significance:

• Documents disease severity and progression
• Gland dropout is irreversible—indicates need for aggressive treatment before further loss
• Useful for patient education and treatment motivation

---

6. Differential Diagnosis

Key Differentials

Red Flag: Sebaceous Gland Carcinoma

This rare but aggressive malignancy (incidence ~1/1,000,000) characteristically mimics chronic blepharitis or recurrent chalazion, leading to delayed diagnosis and increased mortality. [8]

Clinical Clues Suggesting Malignancy:

• Unilateral disease in a typically bilateral condition
• Treatment resistance to standard blepharitis management
• Madarosis (loss of normal lash architecture)
• Loss of lid margin architecture (destruction, nodularity)
• Recurrent "chalazion" in the same location
• Pagetoid spread (diffuse, often unilateral conjunctivitis-like appearance)
• Yellow discolouration of lid margin
• Ulceration or bleeding

Management:

• Low threshold for full-thickness lid biopsy (map biopsies may be needed)
• Refer urgently to oculoplastics/oncology
• May require Mohs surgery, orbital exenteration in advanced cases
• 5-year mortality 18-30% if spread beyond orbit [8]

When to Perform Lid Biopsy

---

7. Investigations

Blepharitis is primarily a clinical diagnosis. Investigations are reserved for atypical presentations, treatment failure, or research settings. [1,2]

Essential Investigations (All Patients)

Additional Investigations (Selected Cases)

Interpreting Meibography Results

---

8. Management

Management Principles

Effective blepharitis management requires:

1. Patient Education: Chronic condition requiring lifelong maintenance; no permanent cure
2. Lid Hygiene (Foundation): Warm compresses, lid massage, lid margin cleaning
3. Tear Film Supplementation: Lubricants tailored to disease subtype
4. Pharmacotherapy: Topical and oral antibiotics where indicated
5. Treatment of Underlying Conditions: Rosacea, Demodex, seborrhoeic dermatitis
6. Advanced Therapies: For refractory cases (LipiFlow, IPL, intraductal probing)

The Lid Hygiene Protocol

Lid hygiene is the cornerstone of blepharitis management, with evidence supporting its efficacy across disease subtypes. [6,9]

Step 1: Warm Compresses (5-10 minutes, once or twice daily)

Purpose: Heat melts inspissated meibum (melting point ~32-35°C), facilitating subsequent expression. [9]

Optimal Temperature: ≥40°C sustained at lid for 10 minutes to be effective

Options (in order of efficacy):

Key Counselling Points:

• Must be sustained warmth—not a brief application
• Re-warm flannel every 2 minutes if using this method
• Should feel comfortably warm, not uncomfortably hot
• Perform over closed eyes
• Continue even when asymptomatic for maintenance

Step 2: Lid Massage (Immediately After Warmth)

Purpose: Express liquefied meibum from glands to restore flow.

Technique:

• Use clean finger pad (or cotton bud)
• Upper lid: massage downward toward lash line
• Lower lid: massage upward toward lash line
• Firm but gentle pressure
• Cover entire lid width with systematic strokes

Duration: 30 seconds to 1 minute per lid

Step 3: Lid Margin Cleaning

Purpose: Remove debris, biofilm, and microbial load from lid margin.

Options:

Technique:

• Apply product to cotton bud or pad
• Scrub along lash line with horizontal strokes
• Clean at lash bases, removing debris
• Rinse if required

Frequency:

• Acute flare: Twice daily
• Maintenance: Once daily or alternate days

Lubricants

Artificial tears address the secondary dry eye component and provide symptomatic relief. [7]

Prescribing Principles:

• Match lubricant to disease type (lipid-containing for MGD)
• Preservative-free for > 4×/day use (to avoid preservative toxicity)
• Night-time gel or ointment for morning symptoms
• Trial and error often needed to find optimal product

Pharmacotherapy

Topical Antibiotics

Technique: Apply to lid margin (not into conjunctival sac) using clean fingertip or cotton bud.

Oral Antibiotics

Evidence: The TFOS DEWS II report and multiple RCTs support oral doxycycline for moderate-severe MGD, particularly with rosacea association. [7,17] Sub-antimicrobial dose (40mg MR) is preferred to reduce antibiotic resistance risk while maintaining anti-inflammatory efficacy.

Contraindications/Cautions for Doxycycline:

• Pregnancy and breastfeeding (absolute contraindication)
• Children less than 12 years (dental staining)
• Photosensitivity (advise sun protection)
• Oesophageal ulceration (take upright with water)
• Drug interactions (antacids, warfarin)

Topical Anti-Inflammatory Agents

Demodex-Targeted Treatment

For confirmed or suspected Demodex blepharitis (cylindrical dandruff). [4,13,14]

Lotilaner (Xdemvy) represents a significant advance—the first FDA-approved treatment specifically for Demodex blepharitis, demonstrating significant mite reduction and collarette improvement in phase 3 trials. [18]

Advanced/Specialist Therapies

For patients refractory to standard management, specialist therapies may be considered. [16,19]

Treatment Ladder by Severity

---

9. Complications

Blepharitis can lead to several local complications, most of which are manageable but some carry significant morbidity. [1,2]

Chalazion vs. Stye (Hordeolum)

---

10. Prognosis and Outcomes

Blepharitis follows a chronic, relapsing-remitting course requiring ongoing management rather than definitive cure. [1,2]

Natural History:

• Without treatment: progressive symptoms, worsening ocular surface disease, potential complications
• With treatment: majority achieve good symptom control with consistent lid hygiene

Prognostic Factors:

Expected Outcomes with Treatment:

• 70-80% achieve good symptom control with consistent lid hygiene [6]
• Complete resolution uncommon; maintenance required
• Exacerbations expected, especially with environmental triggers
• Advanced therapies (LipiFlow, IPL) show benefit for 12+ months in responders

Key Counselling Messages:

1. This is a chronic condition—like eczema or asthma, managed not cured
2. Daily lid hygiene is like brushing teeth—a lifelong habit
3. Symptoms will fluctuate; flares don't represent treatment failure
4. Compliance is the strongest predictor of success
5. Early treatment preserves meibomian glands; late treatment cannot restore lost glands

---

11. Prevention and Screening

Primary Prevention

While blepharitis cannot be entirely prevented, risk reduction strategies include:

• Regular lid hygiene in at-risk individuals (rosacea, seborrhoeic dermatitis, atopy)
• Adequate omega-3 fatty acid intake (though evidence is mixed [12])
• Complete blink habits (especially during screen use)
• Avoiding excessive eye makeup; complete daily removal
• Managing systemic conditions (rosacea, diabetes)

Screening Recommendations

No formal population screening programmes exist. However:

• Patients with rosacea should be asked about ocular symptoms and examined for MGD
• Patients on isotretinoin should be monitored for MGD symptoms
• Elderly patients with dry eye symptoms warrant lid margin examination

---

12. Key Guidelines and Evidence

Major Guidelines

Evidence Summary for Key Interventions

The DREAM Study Controversy [12]

The Dry Eye Assessment and Management (DREAM) Study (NEJM 2018) was a large RCT (n=535) that found no significant benefit of omega-3 supplementation (3000mg/day EPA+DHA) over placebo for moderate-severe dry eye over 12 months.

Interpretation:

• Challenged widespread use of omega-3 for dry eye
• Criticisms: placebo arm received olive oil (which may have beneficial effects); high dropout; study population heterogeneous
• May still be reasonable in patients with MGD and low dietary omega-3 intake
• Current practice: reasonable to suggest, but set appropriate expectations

---

13. Examination Focus

Common Viva Questions

Q1: "Describe the classification of blepharitis and the key clinical features of each type."

Model Answer: "Blepharitis is classified anatomically into anterior and posterior types, though mixed disease is most common.

Anterior blepharitis affects the lash-bearing anterior lid margin and has two subtypes: staphylococcal, characterised by hard, brittle collarettes around lash bases with potential lid margin ulceration and secondary marginal keratitis; and seborrhoeic, with soft, greasy scales and associated seborrhoeic dermatitis elsewhere.

Posterior blepharitis, or meibomian gland dysfunction, affects the meibomian glands in the tarsal plate. Clinical features include capped or pouting gland orifices, lid margin telangiectasia, and abnormal meibum expression—ranging from cloudy to toothpaste-like consistency. MGD is the leading cause of evaporative dry eye.

A third important category is Demodex blepharitis, characterised pathognomonically by cylindrical dandruff clasping the lash base, caused by Demodex folliculorum and D. brevis mites."

Q2: "How would you manage a patient with moderate meibomian gland dysfunction and associated rosacea?"

Model Answer: "I would manage this patient with a multimodal approach addressing both the lid disease and systemic rosacea.

For lid hygiene, I would prescribe daily warm compresses for 10 minutes using a reheatable eye mask to achieve sustained temperature of 40°C, followed by lid massage to express meibum, and lid margin cleaning with commercial wipes.

For pharmacotherapy, I would commence oral doxycycline 100mg daily for 6-12 weeks, utilising its anti-inflammatory properties through MMP inhibition and meibum modification. I would prescribe lipid-containing lubricants such as Systane Complete for evaporative dry eye.

I would refer to dermatology for rosacea management and counsel the patient on sun protection given photosensitivity with doxycycline.

For monitoring, I would review at 6-8 weeks to assess response, and consider advanced therapies like IPL or LipiFlow if response is suboptimal, as these have particular efficacy in rosacea-associated MGD."

Q3: "What are the red flags in blepharitis that should prompt further investigation?"

Model Answer: "The critical red flags that should raise concern for alternative diagnoses, particularly sebaceous gland carcinoma, are:

1. Unilateral disease—blepharitis is characteristically bilateral
2. Treatment resistance—not responding to 6-8 weeks of standard therapy
3. Madarosis—loss of eyelashes, especially if localised
4. Recurrent chalazion at the same location
5. Pagetoid spread—diffuse, chronic unilateral conjunctivitis-like appearance

These should prompt urgent ophthalmology referral for full-thickness lid biopsy to exclude sebaceous gland carcinoma, which masquerades as chronic blepharitis and carries significant mortality if diagnosis is delayed."

Q4: "A patient asks why their blepharitis keeps returning despite treatment. How do you counsel them?"

Model Answer: "I would explain that blepharitis is a chronic inflammatory condition, similar to eczema or asthma, that is managed rather than cured. The underlying tendency for meibomian gland dysfunction or lid margin inflammation persists, even when symptoms are controlled.

I would use the analogy of dental hygiene—just as we brush our teeth daily to prevent problems recurring, lid hygiene needs to become a lifelong daily habit. When symptoms are well controlled, maintenance once daily or every other day is usually sufficient, but during flares, twice-daily treatment is needed.

I would emphasise that recurrences don't represent treatment failure but are expected fluctuations, often triggered by environmental factors like screen use, air conditioning, or stress. The key to long-term success is consistent preventive lid hygiene rather than reactive treatment of flares."

Common Examination Mistakes

❌ Mistakes that fail candidates:

• Failing to mention the unilateral blepharitis red flag for malignancy
• Describing meibum expression without knowing the quality grading
• Not knowing the difference between anterior and posterior subtypes
• Forgetting to mention rosacea screening in MGD patients
• Prescribing prolonged topical steroids without acknowledging risks
• Not counselling patients about the chronic nature of the condition

---

14. Patient Information

What is Blepharitis?

Blepharitis is inflammation of the eyelids—one of the most common eye conditions. It causes red, sore, itchy, gritty-feeling eyes that may be crusty, especially in the morning. It happens when the tiny oil glands near your eyelashes don't work properly or when bacteria build up on your eyelids.

Why Does It Happen?

The most common cause is a problem with the small oil glands in your eyelids called meibomian glands. These normally produce an oily layer that stops your tears evaporating too quickly. When they become blocked or produce abnormal oil, your eyes feel dry and irritated.

Other causes include:

• Bacteria on the eyelid skin
• Tiny mites called Demodex (more common as we get older)
• Skin conditions like rosacea or seborrhoeic dermatitis (dandruff)

Is There a Cure?

There is no quick cure, but blepharitis can be very well controlled. Think of it like looking after your teeth—you need to clean your eyelids regularly, just as you brush your teeth every day. Most people find their symptoms improve significantly with regular lid hygiene.

What Should I Do? (Lid Hygiene Routine)

Do this once or twice daily:

1. Warm Compress (10 minutes): Place a warm (not hot), reheatable eye mask or warm flannel over your closed eyes for 10 minutes. This melts the blocked oils in your glands.

2. Massage (1 minute): Immediately after, gently massage your eyelids. Push downward on the upper lids and upward on the lower lids toward your lashes. This helps push the melted oil out.

3. Clean (1-2 minutes): Use a lid wipe, or a cotton bud dipped in diluted baby shampoo, to clean along your lash line, removing any crusts or debris. Rinse if needed.

What Else Helps?

• Eye drops: Artificial tears (lubricants) help with dryness and grittiness
• Avoid heavy eye makeup during flares
• Remove makeup thoroughly every night
• Take breaks from screens (blink more!)
• Stay hydrated and eat a healthy diet

When Should I See a Doctor?

See a doctor if:

• Your symptoms aren't improving after 4-6 weeks of lid hygiene
• Only one eye is affected
• You're losing eyelashes
• You have pain, significant redness, or vision changes
• You get a painful lump that doesn't settle

Key Counselling Points for Clinicians

1. Set Realistic Expectations: "This is a long-term condition. We manage it, we don't cure it."
2. Emphasise the Routine: "Lid hygiene is the most important treatment—even more than drops."
3. Demonstrate Technique: Show patients correct warm compress and massage technique
4. Sustained Warmth: "The compress needs to stay warm for 10 minutes—reheatable masks work better than flannels."
5. Compliance is Key: "The more consistently you do this, the better your symptoms will be."
6. Expect Fluctuations: "Flares will happen—it doesn't mean treatment has failed."

---

15. Historical Context and Etymology

• "Blepharitis": From Greek blepharon (eyelid) + -itis (inflammation)
• "Meibomian Glands": Named after Heinrich Meibom (1638–1700), German physician and anatomist who first described these glands in De Vasis Palpebrarum Novis (1666)
• "Demodex": From Greek demos (fat, lard) + dex (wood-worm)—literally "fat worm"

The modern understanding of MGD as a distinct entity emerged from the TFOS International Workshop on Meibomian Gland Dysfunction (2011), which brought together international experts to standardise definition, classification, diagnosis, and management. [2] This landmark publication transformed the field by recognising MGD as the leading cause of evaporative dry eye.

---

16. References

1. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(2 Suppl):S1-S14. doi:10.1016/S1542-0124(12)70620-1

2. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929. doi:10.1167/iovs.10-6997a

3. Arita R, Itoh K, Maeda S, et al. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology. 2009;116(11):2058-2063. doi:10.1016/j.ophtha.2009.04.037

4. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094. doi:10.1167/iovs.05-0265

5. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994-2005. doi:10.1167/iovs.10-6997e

6. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050-2064. doi:10.1167/iovs.10-6997g

7. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-283. doi:10.1016/j.jtos.2017.05.008

8. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151-2157. doi:10.1016/j.ophtha.2004.07.031

9. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29(2):96-99. doi:10.1097/01.ICL.0000060998.20142.8D

10. Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017;15(3):284-333. doi:10.1016/j.jtos.2017.04.001

11. Moon JH, Kim KW, Moon NJ. Smartphone use is a risk factor for pediatric dry eye disease according to region and age: a case control study. BMC Ophthalmol. 2016;16(1):188. doi:10.1186/s12886-016-0364-4

12. Dry Eye Assessment and Management Study Research Group. n-3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378(18):1681-1690. doi:10.1056/NEJMoa1709691

13. Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC. Corneal manifestations of ocular Demodex infestation. Am J Ophthalmol. 2007;143(5):743-749. doi:10.1016/j.ajo.2007.01.054

14. Li J, O'Reilly N, Sheha H, et al. Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with facial rosacea. Ophthalmology. 2010;117(5):870-877. doi:10.1016/j.ophtha.2009.09.057

15. Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea—a review. Arq Bras Oftalmol. 2012;75(5):363-369. doi:10.1590/S0004-27492012000500016

16. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016;10:1385-1396. doi:10.2147/OPTH.S109663

17. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32(1):44-53. doi:10.1097/ICO.0b013e318254205f

18. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn-1 Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2023;42(4):435-443. doi:10.1097/ICO.0000000000003097

19. Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019;17(1):104-110. doi:10.1016/j.jtos.2018.11.011

20. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.011

---

17. OTC Product Recommendations (UK/International)

Lid Hygiene Products

Lubricant Eye Drops

---

18. Referral Pathways

When to Manage in Primary Care

• Mild bilateral blepharitis responding to lid hygiene
• No corneal involvement
• No red flag features

When to Refer to Ophthalmology

---

19. Audit Standards and Quality Markers

---

20. Quick Reference: Differential by Clinical Finding

---

21. Patient Frequently Asked Questions

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Evidence and guidelines are current as of the last updated date. Individual patient management should be based on clinical judgement and local protocols. If you have persistent eye symptoms, please consult an optometrist or ophthalmologist.